抗银屑病药物对女性的疗效是否优于男性?
该研究从瑞士和德国患者登记库中纳入5346例接受系统治疗的成年银屑病患者(60%为男性),随访至治疗后1年,发现女性在银屑病面积与严重程度指数(PASI)和皮肤病生活质量指数(DLQI)两个量表上的改善优于男性。作者认为这可能与女性用药依从性更好、体重较低(平均91 kg vs 78 kg)及体脂比例较高等因素有关,提示需要结合性别进行更个体化的治疗。
要点
- 女性银屑病患者在PASI和DLQI两个量表上的改善均优于男性。
- 男性平均体重91 kg,女性平均体重78 kg,同等剂量下女性每公斤组织剂量更高。
- 作者认为结果可能与女性用药依从性更好、体重较低及体脂比例较高有关。
核心结论
- 女性在接受系统抗银屑病药物治疗后,PASI和DLQI两个量表的改善均优于男性。
- 作者认为这些发现提示需要结合性别进行更个体化的治疗。
研究设计与样本
- 研究从瑞士和德国患者登记库中识别出5346例成年银屑病患者,其中60%为男性。
- 所有患者均接受系统药物,包括非生物制剂(甲氨蝶呤、富马酸酯类、环孢素、阿维A或阿普米司特)或生物制剂(阿达木单抗、依那西普、英夫利西单抗、乌司奴单抗或司库奇尤单抗)。
- 患者自开始治疗后随访至1年。
主要发现
- 男性平均体重91 kg,女性平均体重78 kg。
- 治疗开始时男性银屑病严重程度更重,而女性生活质量评分更差。
- 随访至治疗后1年,女性在PASI和DLQI两个量表上的改善均优于男性。
- 作者认为结果可能反映女性用药依从性更好,或与其体重较低有关,即男女使用相同剂量时女性每公斤体组织接受的剂量更高。
- 作者还认为由于激素因素,女性体内脂肪比例更高,可能使药物更易在体内分布,且女性对银屑病的负面体验更强,故DLQI有更大改善空间。
临床怎么用
- 作者认为这些发现提示需要结合性别进行更个体化的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Linked Article: Maul et al. Br J Dermatol 2021; 185:1160-1168. Psoriasis is a chronic, scaly skin condition affecting about 2·5% of the population. It has a negative impact on people's quality of life, more so in women. It is usually treated with creams but is sometimes severe enough to need strong medicines, which are not always effective. This study examines differences between men and women in their responses to treatment. The 5346 adult patients were identified from Swiss and German patient registries; 60% were male. The men were heavier than women (average 91 kg versus 78 kg). At the start of treatment men had worse psoriasis whereas women had worse quality of life scores. All received systemic medicines, including non-biologics (methotrexate, fumaric acid esters, ciclosporin, acitretin or apremilast) or biologics (adalimumab, etanercept, infliximab, ustekinumab or secukinumab). They were followed up for up to a year after starting treatment and women showed better improvements on two scales called the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) than men. These results might reflect better drug adherence in women, or their lower bodyweight - where the same dose is used for men and women, women will receive a higher dose per kilogram of body tissue. Also, because of hormonal factors, women's bodies contain a higher proportion of fat, which may allow the drug to spread more easily through the body. Finally, women experience their psoriasis more negatively than men and so there was more room for improvement in DLQI. These findings indicate a need for more personalized treatment, taking gender into account.
引用
- Do anti-psoriatic drugs work better in women than men? Br J Dermatol. 2021. PMID: 34919264. doi:10.1111/bjd.20787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。